초록 ▼

There are provided pediocin-producing pediococci that have an enhanced survival property in the small intestine. The pediococci comprise in particular Pediococcus acidilactici isolated from human faeces. The pediococci are suitable for use in the gastrointestinal tract of humans to provide a health-

There are provided pediocin-producing pediococci that have an enhanced survival property in the small intestine. The pediococci comprise in particular Pediococcus acidilactici isolated from human faeces. The pediococci are suitable for use in the gastrointestinal tract of humans to provide a health-promoting action, in particular against infection by multi-resistant pathogens. Also provided herein are compositions incorporating such pediocin-producing pediococci.

대표청구항 ▼

1-16. (canceled) 17. A method for inhibiting the growth of pathogenic strains in the gastrointestinal tract in a human in need thereof, comprising administering pediocin-producing pediococci to said human, wherein the pediococci are characterized by a survival rate as per the Survival Rate Test

1-16. (canceled) 17. A method for inhibiting the growth of pathogenic strains in the gastrointestinal tract in a human in need thereof, comprising administering pediocin-producing pediococci to said human, wherein the pediococci are characterized by a survival rate as per the Survival Rate Test defined herein of at least 80%. 18. The method according to claim 17, wherein the survival rate is at least 90%. 19. The method according to claim 17, wherein the pediococci are isolated from human faeces. 20. The method according to claim 17, wherein said administration prevents and/or treats infections by pathogenic bacteria in the gastrointestinal tract, diarrhoea, and/or secondary disorders associated herewith. 21. The method according to claim 17, wherein the secondary disorders are selected from the group consisting of water disturbances, mineral balance disturbances, malnutrition, dysfunctioning of tissues, dysfunctioning of organs, dysfunctioning of organism, and combinations thereof. 22. The method according to claim 17, wherein the pediococci comprise Pediococcus acidilactici strain LMG P-21927. 23. The method according to claim 17, wherein the pathogenic bacteria are Gram-negative bacteria. 24. The method according to claim 17, wherein the pathogenic bacteria are Gram-positive bacteria. 25. The method according to claim 17, comprising administering pediocin-producing pediococci in combination with one or more further probiotics selected from the group consisting of Lactobacillus rhamnosus, L. plantarum, L. fermentum, L. acidophilus, L. reuteri, L. casei, L. johnsonii, L. gasseri, L. crispatus, L. helveticus, L. salivarius, L. lactis, L. brevis, L. paracasei, L. sakei, Bifidobacterium animalis, B. lactis, B. adolescentis, B. longum, B. infantis, B. bifidum and B. breve. 26. A method for inhibiting the growth of pathogenic bacteria in the gastrointestinal tract in a human in need thereof, comprising administering pediocin-producing pediococci to said human, wherein the pediococci are isolated from human faeces. 27. The method according to claim 26, wherein said administration prevents and/or treats infections by pathogenic bacteria in the gastrointestinal tract, diarrhoea, and/or secondary disorders associated herewith. 28. The method according to claim 26, wherein the secondary disorders are selected from the group consisting of water disturbances, mineral balance disturbances, malnutrition, dysfunctioning of tissues, dysfunctioning of organs, dysfunctioning of organism, and combinations thereof. 29. The method according to claim 26, wherein the pediococci comprise Pediococcus acidilactici strain LMG P-21927. 30. The method according to claim 26, wherein the pathogenic bacteria are Gram-negative bacteria. 31. The method according to claim 26, wherein the pathogenic bacteria are Gram-positive bacteria. 32. The method according to claim 26, comprising administering pediocin-producing pediococci in combination with one or more further probiotics selected from the group consisting of Lactobacillus rhamnosus, L. plantarum, L. fermentum, L. acidophilus, L. reuteri, L. casei, L. johnsonii, L. gasseri, L. crispatus, L. helveticus, L. salivarius, L. lactis, L. brevis, L. paracasei, L. sakei, Bifidobacterium animalis, B. lactis, B. adolescentis, B. longum, B. infantis, B. bifidum and B. breve. 33. An isolated pediocin-producing pediococcus characterised by a survival rate as per the Survival Rate Test defined herein of at least 90%. 34. The pediococcus according to claim 33, wherein the pediococcus is Pediococcus acidilactici as deposited at BCCM짰/LMG under No. LMG P-21927. 35. A health-promoting composition comprising a pediococcus according to claim 33, as a probiotic component. 36. The health-promoting composition according to claim 35, further comprising a component selected from the group consisting of pediocin, additional probiotics, prebiotics, immunoglobulins, and mixtures thereof. 37. A method for isolating pediocin-producing pediococci from a substrate, wherein the pediocin-producing pediococci is isolated by using a medium comprising xylose, an antibiotic derived from quinolones and pediocin. 38. The method according to claim 37, wherein the substrate is human faeces.